Director/PDMR Shareholding
Notification and public disclosure of transactions by persons discharging managerial responsibilities
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Mary Regina (Nina) Henderson | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-executive Director | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Hikma Pharmaceuticals PLC | ||||
b) | LEI | 549300BNS685UXH4JI75 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | ||||
b) | Nature of the transaction
| Market purchase of 2,000 Ordinary Shares by Mary Regina (Nina) Henderson. | ||||
c) | Price(s) and volume(s) | Price(s): £15.6305 Volume(s): 2,000 | ||||
d) | Aggregated information - Volume - Price |
£31,261.00 | ||||
e) | Date of the transaction | 15 March 2019 | ||||
f) | Place of the transaction | London Stock Exchange (XLON) |
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
15 March 2019
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.